*quote from Prof. Heluljng Kristensen studies, since results can vary widely between laboratories. The administration of a 'cocktaiJ' of several new compounds in whole anima l studies to assess their pemleabilities was presented by Dr. Phil Smith as a way of reducing the number of studies needed to sort out candidates for oral delivery.
In the session on solubility and dissolution, Prof. Gordon Amidon (Universiry of Michigan) laid the groundrules for determining whether a substance fits the BCS criteria for hi ghly soluble or not. Prof. Jennifer Dressman (University of Frankfurt) followed with a discussion of how to establish dissolution conditions that are more representative of those in d,e GI tract. Main areas of concern remain the simulation of fed state conditions in the stomach and trying to reproduce the wide-rangiJlg hydrodynamic conditions in the upper GI tract. Dr. Martin Siewert (Hoechst AG) underscored the need to develop dissolution tests that can be used both as a qua li ty control mechanism and as a measure of bioequivalence. To round off the session, Dr. Bertil Abrahamsson (Astra Hassle, Sweden) presented several iUuminating case examples for successful as we ll as unsuccessful attempts to create dissolution modeJs for the bioavailabiliry of ER products.
Next followed a discussion of various appropriate data analysis techniques. Prof. C hristos Reppas (Universiry of Athens) gave a detailed explanation of how the f2 (simi lariry) factor functions and discussed how the sampling in in vitro studies must be set up in order to assure meaningful comparisons of dissolution profiles. Dr. Dierk Brodaneier (Hoechst AG) followed with a presentation highlighting the clinical side of the in vitro/in vivo coin, discussing both convolution and deconvolution techniques. Dr. Johannes Kramer (ZL) then presented practical examples for the correlation of in vitro and in vivo data using case studies performed at ZL.
On the third day, the emphasis moved to regulatory aspects and the impact of the guidance process. After an introductory overview to the FDA's regulatory policies for oral fonnulations from Dr. Larry Lesko, the Guidances for JR, ER and the BCS were summarized individually by Dr. VUlod Shah, Dr. HankMalinowski and Dr. Ajaz Hussain. In these Dissolution Tedmologies/ AUGUST 1998 dx.doi.org/10.14227/DT050398P17 "Biopharmacy is Back!" ... continued presentations the FDA showed its willingness to consid e r adjustme n ts to th e G uide lin es. Fo r example, Dr. I-Iussain indicated that the requjrement for High Permea bility could probably be loosened to all ow compo un ds wi th pe rm ea bili ties correspondin g to 80 % a bsorp t io n or better to be admitted to this category. It was also brought out that the G uide lin es are m ea nt to ease th e strin ge ncy o f requirements fo r bioequi va lence snldi es, so that certain preparations (es peciall y those 1 R products containin gciass I compounds and E R prod ucts wi th good in vitrolin vivo co rrela tion histori es) could be exempted from bi oequj va lence stud ies.
T he workshop then deviated from its Ameri can precursor, in that the last session was devoted to inte rn atio nal perspectives and the o utlook for har- tio n of po li cy is urgently needed , so th at the indus try is no t overburde ne d with diffe re nces in regulatory approaches tI,at result in bioequi valence studi es havin g to be run o n a coun try-to-coun try bas is. D r. Ko pp-Kubel stressed that the need fo r Dissolution Technologies/AUG UST 1998 substi tu tes fo r bioequiva lence studies is parti cuJ ar-Iy urgent ill th e develo ping nations. An interestin g difference between the Gemlan authori ty's (BfarM's) approach and the F DA approach is that the BfaI'M takes in to consid e ration the the rape uti c ca tegory of the drug substance when deciding whether bioequi val e nce studi es have to be run o r not. T he rapeutic ca tegori es in whi ch an over/ underdosage due to enhanced/ diminished bioava il abili ty coul d lead to grave consequences fo r the patient are in gene ral reqtd re d to un dergo bioequiva le nce testin g. O th e r c ategori es m ay receive exemptio ns. As a furrh er di scussio n po in t, Dr. Ah r ( Baye r AG) introduced the concept that dru gs with fast absorp tion and e liminati o n rates are mo re susceptible to bioinequi va lence than those with lo ng halfli ves. Thus, fro m the E uro pea n pe rs pecti ve, it seems that in add ition to the BeS cri te ri a o f solubility and perm ea bili ty, addi tio nal facto rs su ch as th erape uti c category and pharmacolcin eti cs can also pl ay an impo rtant ro le in the decisio n as to w he th e r bi oequi va le nce studi es are required. It will be inte res tin g to see if a nd how t h e FD A integra tes th ese additio nal concepts in to its thinkin g, and conve rsely, to wha t degree the Euro pea n authoriti es will adopt the BeS concept into th eir po licies. O ne thing is sure, the 150 plus parti cipants fro m 12 diffe re nt countri es all ca me away from th e wo rks ho p with a better understa nding o f the issues in vo lve d in and th e approaches currently being ta ken in rega rd to the regu lation of bioequi va le nce.
